Gracell Biotechnologies Price, Forecast, Insider, Ratings, Fundamentals & Signals

San diego, calif. and suzhou and shanghai, china, may 16, 2022 (globe newswire) -- gracell biotechnologies inc. (nasdaq: grcl) (“gracell” or “company”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported first quarter unaudited financial results for the three months ended march 31, 2022, and provided corporate updates.

Gracell to present longer-term follow-up clinical data evaluating gc012f, an autologous car-t therapeutic candidate dual-targeting bcma and cd19, for the treatment of relapsed/refractory multiple myeloma san diego, calif. and suzhou, china , april 28, 2022 /prnewswire/ -- gracell biotechnologies inc. ("gracell" or the "company", nasdaq: grcl), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of its oral abstract presentation at the 2022 american society of clinical oncology (asco) annual meeting, being held from june 3-7 in chicago, illinois.

San diego, calif. and suzhou, china, april 22, 2022 (globe newswire) -- gracell biotechnologies inc. (nasdaq: grcl) (“gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on form 20-f for the full year ended december 31, 2021 with the u.s. securities and exchange commission (“sec”) on april 22, 2022.

Palo alto, calif. and suzhou, china , april 14, 2022 /prnewswire/ -- gracell biotechnologies inc. ("gracell" or the "company", nasdaq: grcl), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its abstract providing the follow-up clinical data of gc012f in the treatment of relapsed/refractory multiple myeloma (rrmm) has been selected for oral presentation as part of an oral abstract session at 2022 american society of clinical oncology (asco) annual meeting.

Palo alto, calif. and suzhou, china, march 14, 2022 (globe newswire) -- gracell biotechnologies inc. (nasdaq: grcl) (“gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported fourth quarter and full year unaudited financial results for the period ended december 31, 2021, and provided corporate updates.

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of three abstracts that it will present at the European Hematology Association 2022 Hybrid Congress (EHA2022 Congress), being held from June 9 – June 12 in Vienna, Austria.

Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and SUZHOU, China , April 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the early results of a first-in-human clinical study of GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

PALO ALTO, Calif. and SUZHOU, China, March 29, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in April 2022 as follows:

Gracell Biotechnologies, Inc. (GRCL) CEO Dr. William Cao on Q4 2021 Results - Earnings Call Transcript

PALO ALTO, Calif. and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on Monday, March 14, 2022. The management team will host a live audio webcast and conference call at 8:00AM Eastern Time.

The stock price of Gracell Biotechnologies Inc (NASDAQ: GRCL) increased by over 70% during intraday trading today. This is why it happened.

SUZHOU, China and PALO ALTO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming conferences:

SUZHOU, China and PALO ALTO, Calif., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

SUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

Gracell Biotechnologies, Inc. (GRCL) CEO William Wei Cao on Q2 2021 Results - Earnings Call Transcript